Report : North America Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Anti-Viral, Anti-Bacterial, Anti-Fungal, and Others), Range (Narrow Spectrum and Broad Spectrum), Route of Administration (IV, Oral, Topical, and Others), Indication (HIV, Tuberculosis, Respiratory Infection, Pneumonia, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, and Others)
At 3.3% CAGR, the North America Anti-Infective Agents Market is speculated to be worth US$ 5,5179.54 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America anti-infective agents market was valued at US$ 45,331.11 million in 2022 and is expected to reach US$ 55,179.54 million by 2028, registering an annual growth rate of 3.3% from 2022 to 2028. Increasing prevalence of chronic diseases and surging government support for research activities including clinical trials are the critical factors attributed to the market expansion.
The clinical trials industry has seen exceptional growth in the last 10 years. The US Food and Drug Administration (US FDA) revealed in August 2019 that it had awarded 12 new clinical trial research grants that are more than US$ 15 million over the next 4 years to improve the development of medical products for patients with rare diseases. The grants were conferred to principal investigators from industry and academics across the country. The FDA awarded grants through the Orphan Products Clinical Trials Grants Program, which Congress funds to promote the clinical development of medical foods, biologics, drugs, and medical devices to treat rare diseases. Grants are intended to considerably contribute to the marketing approval of products to treat rare diseases and provide essential data for developing such products. For clinical trials of possibly life-changing treatments for patients with rare diseases, the FDA has been offering much-needed financial support for more than 35 years. In addition, the Orphan Products Clinical Trials Grants Program's contributions have supported research that will lead to the marketing approval of treatments for rare diseases in the near future.
COVID-19 Vaccines are developing significantly because more participants are focusing on clinical trials and collaborating to make certain rapid growth and sufficient production capacity. Furthermore, the US government agreed to fund US$ 483 million for Moderna Inc., which developed and tested its Covid-19 vaccine in 2020. The US FDA approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the US. Hence, government funding for research activities and clinical trials is aiding the development of new therapies, thereby boosting the anti-infective agent market.
On the contrary, emergence of anti-infective drugs resistance and their various side effects hurdles the growth of North America anti-infective agents market.
Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment held the largest market share of 46.2% in 2022 with a revenue of US$ 20,950.26 million. Further, it is going to reach US$ 25,096.12 million by 2028 at decent CAGR of 3.3% during the forecasted period.
Based on range, the anti-infective agents market sphere is bifurcated into broad spectrum and narrow spectrum. The former held 61.0% market share in 2022, amassing US$ 27,6555.84 million. It is projected to garner US$ 33,331.54 million by 2028 to expand at 3.2% CAGR during 2022–2028.
Based on route of administration, the market is segmented into topical, oral, IV, and others. With 50.9% share IV segment dominated the market in 2022. It accrued US$ 23,093.15 million in 2022 and is estimated to reach by US$ 27,820.08 million by 2028 at a CAGR of 3.2% during 2022-2028.
Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. The others segment held the largest market share of 43.2% in 2022 with a revenue of US$ 45,331.11 million. Further, it is going to reach US$ 55,179.54 million by 2028 at decent CAGR of 3.3% during the forecasted period.
Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. With 42.8% share of the domain, the hospital pharmacies segment dominated the market in 2022. It accrued US$ 19,395.27 million in 2022 and is estimated to generate US$ 23,787.23 million by 2028 to grow at a CAGR of 3.5% over the forecast period.
Our regional analysis states that US captured 79.6% market share in 2022. It was assessed at US$ 36,084.54 million in 2022 and is likely to hit US$ 44,385.57 million by 2028, exhibiting a CAGR of 3.5% during the forecast period.
Key players dominating the North America anti-infective agents market are Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG among others.
Few of the recent key developments among the top market players are listed below:
- In April 2021, Abbott launched adult vaccination program for flu, typhoid, and more vaccines to safeguard people's health. The program aimed to create awareness regarding immunization in adult populations.
- In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO® (Ebola Zaire Vaccine, Live). ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: firstname.lastname@example.org